Description: Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Armata's lead product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. The Company is also developing and advancing a broad pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa, leveraging its proprietary phage-specific GMP manufacturing capabilities.
Home Page: www.armatapharma.com
ARMP Technical Analysis
4503 Glencoe Avenue
Marina del Rey,
CA
90292
United States
Phone:
858 829 0829
Officers
| Name | Title |
|---|---|
| Dr. Brian Varnum Ph.D. | CEO & Director |
| Mr. Todd R. Patrick MBA | Advisor |
| Mr. Steven R. Martin | Advisor |
| Dr. Wenyuan Shi Ph.D. | Co-Founder & Founding Scientist |
| Ms. Erin Butler | Principal Financial & Accounting Officer and VP of Fin. & Admin. |
| Mr. Duane Alfred Morris BA | VP of Operations |
| Dr. Mina Pastagia M.D., MS | Sr. VP of Clinical Devel. |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5068 |
| Price-to-Sales TTM: | 11.15 |
| IPO Date: | 2011-03-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 69 |